MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/apt.70465

Медицинская библиотека · Alimentary pharmacology & therapeutics · 2025

Clinical Trial: Hepatitis B Virus Genotype and a Combination of End-of-Treatment Biomarkers Predict Severe Flares After Nucleos(t)ide Analogue Cessation.

Furquim d'Almeida Arno, Vanderlinden Axelle, Bourgeois Stefan, Mulkay Jean-Pierre, Sersté Thomas, Struyve Mathieu, Deressa Baro, Sprengers Dirk, de Vos Marie, Callens Jos, Shihao Bao, Reynaert Hendrik, Deltenre Pierre, Janssens Filip, Negrin-Dastis Sergio, Stärkel Peter, Orlent Hans, Van Roey Guy, Verhelst Xavier, Moreno Christophe, Delwaide Jean, Van Steenkiste Christophe, Verlinden Wim, Colle Isabelle, Plissonnier Marie-Laure, Mukadi Benoît Kabamba, Testoni Barbara, Zoulim Fabien, Matheeussen Veerle, Vanwolleghem Thomas

Клиническое исследованиеСтатьяМногоцентровое исследованиеПеревод в очереди

Аннотация

BACKGROUND

Nucleos(t)ide analogue (NUC) cessation can induce a functional cure in chronic hepatitis B virus (HBV) infections, but severe post-cessation virologic relapses (SVRel) and severe biochemical flares (SBF) frequently occur.

AIMS: To identify predictive biomarkers for patients at highest risk for SVRel and SBF.

METHODS

In the multicentre prospective COIN-B trial, start-of-treatment HBeAg-negative, long-term virologically suppressed patients without advanced fibrosis are followed up for 72 weeks after NUC cessation. We performed a predefined exploratory analysis of the associations between HBV genotype, or end-of-treatment (EOT) biomarkers (HBcrAg, HBV RNA, HBsAg, and anti-HBc IgG) and SVRel (HBV DNA > 5 log IU/mL) or SBF (ALT > 10× ULN) within 48 weeks post-cessation.

RESULTS

Of 91 recruited patients, 85 completed 48 weeks of follow-up. SVRel and SBF occurred in 36 (42.4%) and 21 (24.7%) patients, respectively. Genotypes C, D, and E were associated with higher relapse and flare rates, whereas none of the 18 genotype A patients developed SBF. In multivariate analysis, SVRel was independently associated with detectable HBcrAg (aOR 3.93, p = 0.01), and SBF with non-A genotype (aOR 19.03, p = 0.018), detectable HBV RNA (aOR 7.84, p = 0.005), and lower anti-HBc IgG levels (aOR 0.31, p = 0.016). A risk stratification tool, the COBRA score, was developed incorporating HBcrAg, HBV RNA, and anti-HBc IgG. A score ≥ 2 identified patients at increased risk, with 80.0% sensitivity and 90.7% NPV for SBF.

CONCLUSIONS

HBV genotype and EOT biomarkers, including HBcrAg, HBV RNA, and anti-HBc IgG predict SVRel and SBF following NUC cessation. The COBRA score enables pragmatic, individualised risk stratification.

TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT04779970, EudraCT: 2021-001003-32.

Для цитирования: Furquim d'Almeida Arno, Vanderlinden Axelle, Bourgeois Stefan, Mulkay Jean-Pierre, Sersté Thomas, Struyve Mathieu, Deressa Baro, Sprengers Dirk, de Vos Marie, Callens Jos, Shihao Bao, Reynaert Hendrik, Deltenre Pierre, Janssens Filip, Negrin-Dastis Sergio, Stärkel Peter, Orlent Hans, Van Roey Guy, Verhelst Xavier, Moreno Christophe, Delwaide Jean, Van Steenkiste Christophe, Verlinden Wim, Colle Isabelle, Plissonnier Marie-Laure, Mukadi Benoît Kabamba, Testoni Barbara, Zoulim Fabien, Matheeussen Veerle, Vanwolleghem Thomas. Clinical Trial: Hepatitis B Virus Genotype and a Combination of End-of-Treatment Biomarkers Predict Severe Flares After Nucleos(t)ide Analogue Cessation.. Alimentary pharmacology & therapeutics. 2025. DOI: 10.1111/apt.70465.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.